Medicines planning
49 results
Applied filters
Biosimilars
Regularly updated material to support the introduction of aflibercept, golimumab, ranibizumab, ustekinumab and other biosimilars of interest.
Understanding biological and biosimilar medicines
1 August 2025Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions
The licence and supporting evidence for natalizumab biosimilar
14 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Preparing to use aflibercept 2mg biosimilar
3 February 2026Aflibercept 2mg biosimilars for use in ophthalmology are available for NHS use. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
16 January 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Biosimilar and key generic medicines – September 2025 update
11 September 2025An update about biosimilar and key generic medicines to support system mobilisation.
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.